IL-6 is a pro-inflammatory cytokine, and anti-IL6 drugs have been approved by the FDA for COVID-19 patients having systemic inflammation or respiratory failure, as these conditions could be associated with an elevated release of cytokine. Here, IL6 is linked to respiratory failure.